697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)
Thomas Powles, Michiel S. van der Heijden, D. Castellano Gauna, Yohann Loriot, Matt D. Galsky, Daniel P. Petrylak, Osamu Ogawa, S.H. Park, Andrea Necchi, Jia-Lin Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, André P. Fay, Ignacio Durán, Natasha Angra, Amod Gupta, Pengcheng He, William P. Levin, Joaquim Bellmunt
Topics & Concepts
MedicineDurvalumabCarboplatinMetastatic Urothelial CarcinomaInternal medicinePopulationGemcitabineGastroenterologyCisplatinChemotherapyClinical endpointAdverse effectOncologyUrologyNivolumabRandomized controlled trialImmunotherapyCancerBladder cancerUrothelial carcinomaEnvironmental healthBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersEsophageal Cancer Research and Treatment